Chardan

Chardan said it likes Teladoc Inc (NYSE: TDOC)'s prospective acquisition of Best Doctors. The firm sees Best Doctors as a good complementary acquisition with a strong brand and assets at a good price. The Deal Teladoc announced Monday after the market close a deal to buy expert medical...

Shares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...

Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) were trading lower by more than 8 percent Monday morning after the company released Phase 3 results in the New England Journal of Medicine from a study called ATHOS-3, which evaluated the company's therapy LJPC-501 for the treatment of...

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneuropathy, or TTR-FAP, Chardan explained how the results support a pair...

Madhu Kumar of Chardan Capital Markets maintains a Sell rating on Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) ahead of the company's R&D Day on April 24. In a research report published Monday, Kumar highlighted his skepticism surrounding the company's Fast Track designation of Coversin, a...

Biogen Inc (NASDAQ: BIIB) shares were seen up 2.9 percent and Ionis Pharmaceuticals Inc (NASDAQ: IONS) up 4.42 percent on Tuesday following news that the FDA has approved Spinraza for treatment of spinal muscular atrophy. At the same time, shares of rival drug maker AveXis Inc (NASDAQ: AVXS) were...

Following the release of top-line results from the eight-week mid-state study of Esperion Therapeutics Inc (NASDAQ: ESPR)'s bempedoic acid, Chardan said safety concerns on adding it to high-dose statins triggers a question whether there is any market for it. Analyst Gbola Amusa believes if high-...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) top line results from a mid-stage study of Eylea co-formulated with rinuccumab didn't meet its primary endpoint. Chardan's Sell rating was predicated on risks surrounding the Praluent U.S. patent infringement case and Eylea's exposure to...

Globalstar, Inc. (NYSE: GSAT) failed to get enough votes in the five member commission to get special rights to unlicensed spectrum in the 2.4 GHz band. Commissioner Ajit Pai disclosed in a statement on Thursday he voted against TLPS after reviewing the record of the Chairman Wheeler's...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) climbed 7 percent in the pre-market hours after a Wall Street analyst said the company could be bought for $22.50 a share with Sanofi SA (ADR) (NYSE: SNY) or Shire PLC (ADR) (NASDAQ: SHPG) touted as potential acquirers. Acquisition...

Shares of The Medicines Company (NASDAQ: MDCO) made a mysterious parabolic move in Tuesday's afternoon session. At 3:00 p.m. ET, the stock spiked up to the $31.40 level after nearly falling below $31 during the day. Shares of Medicines Company had traded at the $41 level in November 2015...

Shares of GoPro Inc (NASDAQ: GPRO) are under pressure on Thursday after the high-definition camera maker released weaker-than-expected fourth quarter guidance and stated that it would cut 7 percent of its workforce. Shares were trading down about 16 percent and have been on a downtrend since...